Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry
Table 3
Clinical outcomes in crude population at 3-year follow-up.
Total (n = 13,097)
EES (n = 5,137)
BES (n = 2,970)
ZES (n = 4,990)
value
Target lesion failure
895 (6.8%)
350 (6.8%)
203 (6.8%)
342 (6.9%)
0.997
POCO†
1862 (14.2%)
712 (13.9%)
413 (13.9%)
737 (14.8%)
0.364
All-cause death
815 (6.2%)
316 (6.2%)
168 (5.7%)
331 (6.6%)
0.210
Cardiac death
481 (3.7%)
183 (3.6%)
95 (3.2%)
203 (4.1%)
0.118
Myocardial infarction
158 (1.2%)
58 (1.1%)
44 (1.5%)
56 (1.1%)
0.295
Target vessel myocardial infarction
84 (0.6%)
29 (0.6%)
26 (0.9%)
29 (0.6%)
0.191
Any revascularization
1075 (8.2%)
406 (7.9%)
258 (8.7%)
411 (8.2%)
0.463
Target lesion revascularization
428 (3.3%)
173 (3.4%)
114 (3.8%)
141 (2.8%)
0.043
Stent thrombosis‡
85 (0.6%)
34 (0.7%)
22 (0.7%)
29 (0.6%)
0.685
Major bleeding
167 (1.3%)
77 (1.5%)
27 (0.9%)
63 (1.3%)
0.074
Values are n (%), unless otherwise indicated. Target lesion failure defined as a composite of cardiac death, MI (not clearly attributed to a nontarget vessel), or target lesion revascularization. †POCO includes all-cause mortality, any MI (includes nontarget vessel territory), and revascularization. ‡Stent thrombosis includes definite and probable stent thrombosis. EES = everolimus-eluting stent; BES = biolimus-eluting stent; ZES = zotarolimus-eluting stent; POCO = patient-oriented composite outcome; MI = myocardial infarction.
